Dossier
atacicept
Coverage of atacicept in the Nexus archive.
- First-in-Class Drug Approved for IgA Nephropathy
The FDA granted accelerated approval to atacicept (Trutakna) for reducing proteinuria in adults with primary IgA nephropathy at risk of disease progression. Approval was supported by data from the ORIGIN 3 trial for the once-weekly self-administered drug.
- STAT+: Radiopharmaceutical shows promise in post-Pluvicto setting
A radiopharmaceutical shows promise in the post-Pluvicto setting. Vera Therapeutics and the FDA agreed to accelerate analysis of a Phase 3 study for atacicept in treating IgA nephropathy, while Abivax reported positive data for an ulcerative colitis treatment despite cancer concerns.